Sign In
Buy FHTX
$3.64
+0.0100 (+0.275%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics: Ifs, Buts, And Clinical Holds
05:08pm, Wednesday, 16'th Aug 2023
Foghorn Therapeutics Inc. stock has increased by 70% in the last 4 months after a clinical hold on their lead program was lifted. Foghorn's technology, called "gene traffic control," aims to regulate
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates
09:47am, Friday, 04'th Aug 2023
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.66 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains?
05:44am, Monday, 10'th Jul 2023
Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further str
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
09:54am, Monday, 08'th May 2023
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.65 per share a year ago.
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?
06:05am, Thursday, 27'th Apr 2023
Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further str
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
04:05pm, Tuesday, 25'th Apr 2023
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases
Foghorn Therapeutics stock slides 21% after FDA puts partial clinical hold on cancer drug trial
07:20am, Monday, 24'th Apr 2023
Foghorn Therapeutics Inc.'s stock FHTX slid 21% in premarket trade Monday, after the biotech said the Food and Drug Administration has placed a partial hold on a cancer trial. The company is pausing e
CAMBRIDGE, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
09:53am, Thursday, 09'th Mar 2023
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -16.95% and 58.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
01:49pm, Thursday, 16'th Feb 2023
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
09:48am, Tuesday, 08'th Nov 2022
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -3.33% and 30.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
07:00am, Thursday, 20'th Oct 2022
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics: Selling For Less Than Cash Value
05:27pm, Monday, 10'th Oct 2022
Today, we put Foghorn Therapeutics in the spotlight for the first time. The company is developing several early stage drug candidates, and the stock trades currently for less than the net cash on the
